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Abstract 
 
In Norway, consumption of psychotropic drug is increasing concomitant with huge variations 
across the counties. The main purpose of this research is to analyze the regional variation of 
consumption of psychotropic drug and identify the responsible factors for these variations. Using 
eight-years, 2004-2011, panel data analysis techniques for 19 counties, we provided fixed effect 
model to analyze the effect of some selective explanatory variables and different counties on the 
use of psychotropic drug. Our main result shows that consumption of psychotropic drug 
responded positively with higher education, higher population density, taking social assistance, 
age group 35-44, age group 45-69, age group 70-79, and age group 80+ and negatively 
responded with higher temperature, non-Norwegian ethnicity, GP density, and unemployment 
rate. We also found a clear north south difference with respect to psychotropic drug 
consumption. People living in Southern part of Norway consumed more psychotropic drug than 
those live in the Northern part. 
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1  Introduction 
Number of persons who had at least one prescription is increasing in Norway with the total 
population. Between 2004 and 2011 the percentage of people who took at least one prescription 
drug increased almost14 percent whilst the total population of Norway increased nearly 7 percent 
that is a sign of growing sickness. By the sexual split, 76.41 percent women had at least one 
prescription at 2010 where 63.04 percent male had it (NorPD). Drug used for nervous system 
(group N under ATC) has emerged as a 2nd largest consumed drug after cardiovascular system 
(group C under ATC) in Norway according to the DDD per 1000 inhabitants per day (DID) 
(NorPD). In 2004, total consumption of drugs for nervous system was 154.34 DID which 
increased to 195.79 DID by 2011 (NorPD). 
 
Among all the prescribed drugs for nervous system, three drugs, antidepressant, anxiolytics, and 
hypnotics and sedatives, are most consumed drugs in Norway. ``Anxiolytic drugs are agents that 
alleviate anxiety, tension, and anxiety disorders, promote sedation and have a calming effect 
without affecting clarity of consciousness`` (Hausken 2010). In Norway most commonly used 
anxiolytics are benzodiazepines (BZDs) (Rønning 2010). ``Hypnotics and sedatives are used to 
induce drowsiness or sleep or to reduce psychological excitement or anxiety`` (Hausken 2010). 
Main two drug groups for Hypnotics and sedatives (insomnia) in Norway are BZD related 
hypnotics (z hypnotics) and BZDs (Rønning 2010). ``Antidepressants are mood-stimulating 
drugs used in the treatment of depressive disorders`` (Hausken 2010). Selective serotonin 
reuptake inhibitors (SSRIs) are the most used antidepressant drugs (two-thirds) in Norway 
(Rønning 2010). By 2011, about 59 percentage of the total consumed nervous system drugs were 
these three drugs. Total consumption of these three drugs experienced an average annual increase 
in 1.95% between 2004 and 2011. Total consumption of these three drugs was about 104 DID in 
2004, and increased to 116 DID by 2011 (NorPD). Aggregate value of these three drugs used as 
psychotropic drug in this study. 
 
Norway is divided into 19 counties (fylker) that are Akershus, Aust-Agder, Buskerud, Finmark, 
Hedmark, Hordaland, Møre og Romsdal, Nordland, Nord-Trøndelag, Oppland, Oslo, Rogaland, 
Sogn og Fjordane, Sør-Trøndelag, Telemark, Troms, Vest-Agder, Vestfold, and Østfold and 
there are large differences in prescription of psychotropic drugs among the counties. Østfold was 
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the highest consumed aggregate psychotropic drugs (antidepressant, anxiolytics, and hypnotics 
and sedatives), DID 148.31, where Troms was the lowest by 83.60 DID in 2011 (NorPD). In 
reference of anxiolytics drug, Telemark consumed 25.25 DID which was the highest among the 
counties while Sogn og Fjordane consumed only 9.59 DID in 2011 (NorPD). Consumption of 
antidepressant drug among the counties also vary enormously, highest consumed by Østfold 
(74.79 DID) and lowest by Troms (37.60 DID) in 2011 (NorPD). On the other hand Aust-Agder 
and Finmark were the two extreme user of hypnotics and sedatives drug use among the different 
counties in 2011. Aust-Agder was highest user of hypnotics and sedatives drug by 58.54 DID 
and Finmark was the lowest by 30.75 DID (NorPD). Consumption of different psychotropic 
drugs (aggregate and separately) by the highest user (county) is almost double than lowest user, 
which ensure the huge difference in prescription of psychotropic drugs use among the different 
counties in Norway.   
 
Objectives and research question of the study: 
The objective of this study is to analyze the prescription of different psychotropic drugs in 
different counties in Norway from 2004 until 2011 based on different socio economic variables 
and find out the main reasons of regional variations in prescription of different psychotropic 
drugs. In that case the research question is: 
 
Which factors are responsible for the regional variation in prescription of psychotropic drugs use 
in Norway?  
To answer the research question this study used econometric estimation and graphical 
information system (GIS) where different socio economic variables and different counties were 
the key variables. A fixed effect panel data model is used for the analysis of psychotropic drug 
use. Hausman test also conducted for the choice whether fixed effects or random effect is fit for 
this data set. Finally this study used GIS to show the regional variation of psychotropic drug use 
after the econometric analysis. 
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Organizations of the study: 
The remainder of this study is organized as follows. Section two provides some background of 
the nervous system drugs, importance of three drugs (antidepressant, anxiolytics, and hypnotics 
and sedatives) as psychotropic drug, and the use of different psychotropic drugs (aggregate and 
separately) in different counties in Norway. A review of relevant literature is provided in section 
three. Section four defines the variables to be used and develops the methodology that is to be 
used for the analysis in section five. The results of the analysis are presented in section five and 
the insights are discussed in section six. Finally, section seven provides a conclusion and further 
develops policy implications. There is a section that addresses the limitations of the study. 
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2  Background 
2.1 Consumption of nervous system drugs (Group N under ATC) 
By 2011, nervous system drugs have become second largest consumed drug under ATC drug 
groups in Norway and the consumption trend of this drug is upward which demands further 
attention.  
Figure 1: Trend of Nervous system (Group N under ATC) drugs use in Norway in 2004-2011 
 
Figure 1 represents the total consumption of drugs used for nervous system (group N) by DID 
between the periods 2004-2011. In every year between 2004 and 2011, nervous system drugs 
consumption increased but steadily and finally it experienced 195.79 DID in 2011 as second 
largest consumed group under ATC in Norway. Between 2004 and 2011, drugs for nervous 
system increased by nearly 41 DID by average 3.48% growth in each year. 
2.2 Importance of three drugs, antidepressant, anxiolytics, and hypnotics and 
sedatives, as psychotropic drug  
The use of psychotropic drugs is increasing in Norway. Antidepressant, anxiolytics, and 
hypnotics and sedatives are most used psychotropic drugs there by contributing more than half of 
the total psychotropic drugs.  
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Table 1: Consumption of antidepressant, anxiolytics, hypnotics and sedatives, and aggregate of 
three drugs (as psychotropic drug) by DDD per 1000 inhabitants per day (DID) and % share of 
total drugs for nervous system (group N under ATC) 
Source: NorPD 
Consumption of nervous system drugs is highly dependent on three drugs, antidepressant, 
anxiolytics, and hypnotics and sedatives. The contribution of these three drugs in total nervous 
system drugs consumption was about 59 percent in 2011 where individual share of 
antidepressant, anxiolytics, and hypnotics and sedatives was nearly 28%, 9%, and 23%, 
respectively. But in 2004, the share of aggregate three drugs, antidepressant, anxiolytics, and 
hypnotics and sedatives was almost 68%, 32%, 12%, and 24%, respectively. Even though the 
share of these drugs decreased from 2004 to 2011, the total consumption increased except 
anxiolytics. Antidepressant drug consumption increased by almost 6 DID while hypnotics and 
sedatives increased by 8 DID and anxiolytics decreased by almost 2 DID. In reference of 
aggregate of these three drugs (psychotropic), total consumption was increased by almost 12 
DID between 2004 and 2011.    
2.3 Consumption of psychotropic (Aggregate three drugs), antidepressant, 
anxiolytics, and hypnotics and sedatives drugs in different counties in Norway 
Norway is divided into 19 counties (fylke) and has large geographical variation. Counties differ 
not only by geographically but also socioeconomically and culturally. Different psycho tropical 
drugs consumption also varies across the counties.    
 
Year  Antidepressant  Anxiolytics  Hypnotics and 
sedatives 
 Aggregate of 
three drugs 
DID Share DID Share DID Share DID Share 
2004 49.05 31.78 19.16 12.42 36.29 23.51 104.50 67.71 
2005 49.23 29.95 19.67 11.97 39.33 23.93 108.24 65.84 
2006 50.01 29.27 19.38 11.34 41.21 24.12 110.61 64.73 
2007 52.33 29.12 19.32 10.75 43.36 24.12 115.01 63.99 
2008 53.32 28.40 19.52 10.40 44.76 23.84 117.60 62.64 
2009 53.35 27.90 19.20 10.04 45.27 23.68 117.82 61.61 
2010 54.61 28.08 18.31 9.41 45.07 23.17 117.98 60.66 
2011 55.28 28.23 16.90 8.63 44.22 22.58 116.40 59.45 
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Figure 2: Psychotropic (aggregate three) drug use in different counties in Norway (2011) 
 
 
Figure 2 shows the large differences in psychotropic drugs used across counties in Norway 
according to defined daily dose per 1000 inhabitants per day (DID) in 2011. Relatively high 
consumption of psychotropic drugs by DID was observed in Østfold, Telemark, Oppland, and 
Aust agder whereas Troms and Finmark had less consumption among 19 counties. Average 
consumption of psychotropic drugs by 19 counties were 116.40 DID where greatest consumed 
by Østfold (148.31) and lowest consumed by Troms (83.6). The difference between highest and 
lowest consumption was large (almost 66 DID) that ensures a distinct variation across counties 
with respect to psychotropic drug consumption. 
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Figure 3: Antidepressants drug use in different counties in Norway (2011) 
 
Figure 3 represent the variation of antidepressant drug consumption by different counties in 
Norway by 2011. The average consumption of antidepressant was 55.28 DID where highest 
consumption was attained by Østfold (74.79 DID) and lowest consumption attained by Troms 
(37.60 DID).  
Figure 4: Hypnotics and sedatives drug use in different counties in Norway (2011) 
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Figure 4 gives a clear idea about the regional variation of hypnotics and sedatives drug use in 
Norway. Comparing the consumption data in 2011, Aust-Agder was among counties with high 
consumption rates of hypnotics and sedatives while Sogn og Fjordane had less consumption. 
Total number of hypnotics and sedatives drug consumption (58.54 DID) in Aust-Agder was 
almost 99% higher than the consumption (29.43 DID) by Sogn og Fjordane.  
Figure 5: Anxiolytics drug use in different counties in Norway (2011) 
 
Looking at the consumption structure of anxiolytics, figure 5 suggests that there was a huge 
variation in anxiolytics consumption between counties in Norway. The lowest consumption by 
Sogn og Fjordane was almost 9.59 DID whereas average consumption by all counties was 16.90 
DID in 2011. In contrary highest consumption by Telemark was 25.25 DID which is more than 
the double of lowest.      
Figure 2, 3, 4, and 5 depicted a clear regional variation of psychotropic, antidepressant, 
anxiolytics, and hypnotics and sedatives drugs consumption in different counties in Norway. In 
the case of all of these drugs, greatest consumed county had almost the double than that of the 
lowest consumed county which is a cause of concern.     
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3  Review of Literature 
Bocquier et al. (2008) analyzed the geographic variation of dispensing anxiolytics (AX) and 
hypnotics (HY) drugs use in southeastern France at the canton level and tried to find out 
responsible demographic factors and determinants for that kind of variation. They used only one 
year (2005) data and prevalence of chronic illnesses, GP density (per 100000 persons) and 
several demographic and socioeconomic factors for analysis. They used the ratio of population 
who had at least one prescription of AX or HY and number of population who were included in 
general health insurance fund in 2005. On the other hand individual who had six or more 
prescriptions were considered as chronic ill. They calculated age adjusted prevalence for men 
and women separately. In this study social and demographic factors were percentage of 
population in four age groups less than 20 years, 45-59 years, 60-74 years and 75 or more, 
percentage of single parent families, percentage of old people living alone, and population 
density (per km²) and socioeconomic factors were unemployment rate, average annual family 
income, occupational categories that were divided into managerial and professional employees, 
office workers, and manual workers, proportion of inadequate housing, and subsidized housing. 
To find out the effect of age and gender on prescribing AX-HY drugs they used descriptive 
statistical analysis where they estimated relationship between chronic use and prescribing AX-
HY drugs by the Pearson correlation coefficient. They also calculated the extremal quotient 
(EQ), the ratio of the highest rate to the lower rate, and the weighted coefficient of variation 
(COV), the ratio of the standard deviation of the rates (among cantons) to the mean rate (among 
cantons) weighted by the population in each canton, to measure the variation between different 
cantons. They also used simple and multiple regression analysis to measure the effect of different 
potential determinants on age adjusted prevalence of AX-HY drugs use for men and women 
separately.  
From the descriptive analysis they showed that in every age group, prevalence of AX-HY is 
higher for women than for men, and it increased with age. From the Pearson correlation 
coefficient chronic illness has high effect for both men and women. By the EQ and COV they 
showed the statistically significant geographic variation exist in different cantons. Among the 
different demographic and socioeconomic determinants average family income, unemployment 
rate, and chronic illness are positively related to the AX-HY dispensing for men. On the other 
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hand results for women are almost same where with these results percentage of subsidized 
housing also have positive effect on AX-HY dispensing has.   
Kjosavik et al. (2009) used antipsychotics, anxiolytics, hypnotics and antidepressants as 
psychotropic drug to analyze the use of psychotropic drugs in Norway. Based on 2005 data they 
used gender and six age groups (less than 20years, 20–39 years, 40–59 years, 60–69 years,70–79 
years  and 80 years and older) as the explanatory variables. By using descriptive statistical 
analysis they calculated the positive dependency of psychotropic drugs use with female and age. 
They concluded that female use more psychotropic drug than male and it increases with age.  
Wells et al. (1985) conducted a study within six US cities by self-administered enrollment 
questionnaire within age of 18 years or older.  They used sleeping pill and tranquilizer as 
psychotropic drug and age, sex, education, race, income, site and marital status as explanatory 
variables. To calculated the effect of explanatory variables they played multiple and logistics 
regression analysis for each of two psychotropic variables. They found that Women have used 
both sleeping pill and tranquilizer more than men and use of these two drugs increased with age. 
They did not find any statistically significant effect of high income, education level and race on 
sleeping pills. But the effect of high income level has a positive effect on tranquilizer use. They 
also found the higher prevalence of taking tranquilizer among more educated persons than lower. 
On the other hand non-black persons take more tranquilizer than black. Other two factors site 
and marital status have no significant effects on sleeping pills and tranquilizers use.    
Lorant et al. (2007) conducted a study to assess the relationship between socioeconomic status 
and common mental problem, depression, by using seven year periods. For the socioeconomic 
status they considered three measures that are social relationship, skills, and material standard of 
living. They assessed the social relationship by living arrangements and civic participation where 
unemployment and educational status used as skills. They also considered subjective financial 
strain, deprivation, income, and poverty to measure the material standard of living. To estimate 
the effect they used fixed effect model. They also used conditional logistic regression for binary 
response as equivalent of fixed effect model. By using probit model they calculated inverse Mills 
ratio to correct the selection bias,(loss to follow up could result in bias if poor people and those 
with depression are more likely to be lost to follow-up than those who are well off and not 
depressed), from the model and used it an additional explanatory variable in the model. After 
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that they used Heckman selection model for the panel data fixed effect model. From the study 
they found a positive effect of increased financial strain, poverty, and deprivation on depression. 
They also found a negative relationship between depression and living with partner or spouse, 
and civic participation. But they did not find any statistically significant effect of unemployment 
and household income on depression.  
 
Kaplan et al. (1987) analyzed the epidemiology of depression by using seventeen explanatory 
variables within four groups such as status attributes, personal resources, life stress, and physical 
health. Status attributes included marital status, age, ethnicity, sex, income, and education while 
personal resources measured by health behavior (alcohol consumption, smoking, usual sleep 
patterns, physical activity in leisure time), personal uncertainty,  anomy, and social isolation and 
physical disability or presence of chronic conditions. Other group life stress measured by 
residential move, divorce or separation, death of partner or spouse, money problems, and loss of 
a job. Ailments, symptoms, and health condition represented the physical health. They used 
multiple logistic regression models and found that depression symptoms are strongly related with 
anomy, job loss, physical disability or presence of chronic conditions, social isolation, low 
education, personal uncertainty, money problem, residential move and baseline depressive 
symptoms. But baseline health practices, divorce or separation, age, marital status, ethnicity and 
low income were not associated with symptoms of depression. 
Isacson and Haglund (1988) conducted a study on Swedish community to discover the 
relationship between psychotropic drugs use and socioeconomic and demographic risk factors. 
By the using of descriptive statistical and multivariate logistic analysis they found that distance 
to the health center, socioeconomic status, gender , marital status, and age have significant effect 
of psychotropic drugs use. They showed that psychotropic drugs use is positively associated with 
increased age, short (less than 5 km) distance of health care, female than male and divorced 
person than married person.   
Colman et al. (2008) conducted a study on a group of population over seventeen years to explore 
the risk factors of antidepressant, anxiolytic, and hypnotic. They used clinical and non-clinical 
factors that are associated with these three psychotropic drugs use. Non clinical factors measured 
by socio demographic factors (sex, living alone, marital status, employment status) and clinical 
factors measured by poor physical health, sleep difficulties, suicidal ideation and history of 
12 
 
psychiatric symptoms. By using logistic analysis they found strong association between 
antidepressant, anxiolytic, and hypnotic drug use and clinical factors. On the other hand 
antidepressant, anxiolytic, and hypnotic drug use is less consistently associated with non-clinical 
factors.  
Lund et al. (2010) tried to find out the association of common mental disorders (CMD) with the 
level of poverty in low and middle income countries (LMIC). In their research study they have 
used depression, anxiety and somatoform disorders as common mental disorders and they also 
have used some exposure variables that are employment status, income, education, social class 
and socio-economic status (SES), financial stress, housing and living environment (structural), 
consumption, water and sanitation, housing and living environment (overcrowding), and food 
insecurity to measure the poverty. They reviewed total 115 previous related literatures from last 
19 years. They found a positive association between CMD and poverty where such variables 
education, financial stress, housing, socio-economic status, social class and food insecurity are 
strongly related with CMD. Other variables such as employment status, consumption and income 
are ambiguous. 
From reviewed of literatures we found some socioeconomic variables, disable persons, level of 
education, ethnicity, average income level, density of general practitioner (GP), living alone, 
smoking habit, unemployment rate, married person, and different age groups, have effect on 
different psychotropic drugs use and these factors are also appropriate for our study. Besides 
these responsible factors we also considered some other factors, average temperature, average 
precipitation rate, population density, and social assistance, as dependable factors for 
psychotropic drugs use in this study. 
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4  Data and Methodology 
4.1 Data sources and description of variables: 
This study was formulated by secondary data collected from the different sources. Total drugs 
consumption data were taken and constructed from the Norwegian prescription database (on-line 
database). Temperature and precipitation data collected from Norwegian meteorological 
institute. Other variables disability, level of education, ethnicity, income, density of general 
practitioner (GP), population density, living alone, smoking, unemployment rate, married person, 
social assistance, and different age groups were collected from the Statistics Norway. 
In this study we dealt with three types of drugs, antidepressant, anxiolytics and hypnotics from 
central nervous system (CNS). We used these three types of drugs separately and we also used 
aggregate value of these drugs for the term psychotropic drug in this research. Anxiolytics, 
hypnotics and antidepressants, these three categories of drugs explained by the Anatomical 
Therapeutic Chemical (ATC) codes N05B, N05C and N06A respectively.  
 
The Anatomical Therapeutic Chemical (ATC) drug classification system is the most acceptable 
drug classification system in the research of drug utilization (Vlahovic´-Palcˇevski et al. 2010) 
and it also widely used and most useful method in drug consumption research for classifying 
therapeutic substances into classes (Hutchinson et al.2004).  World Health Organization (WHO) 
recommended this drug classification for the global use. The drug measurement unit Defined 
Daily Dose (DDD) is integrated with ATC classification system. ``The DDD is the assumed 
average maintenance dose per day for a drug used for its main indication in adults. This is a 
technical unit of measurement, not a standard for appropriate use, and it does not necessarily 
reflect the actual daily dosage most commonly used in a country`` (Vlahovic´-Palcˇevski et al. 
2010) (WHO Collaborating Centre for Drug Statistics Methodology). We have used defined 
daily dose (DDD) per 1000 inhabitants per day to measure the drugs consumption. 
Short descriptions of different independent variables are as follows: 
Temperature: Average temperature in a calendar year in degree Celsius.  
Precipitation: Total precipitation in a year in liter. 
14 
 
Disability: Percentage of population (18-67 years) who receive disability pension. 
Level of education: Percentage of population who have at least higher secondary education. 
Ethnicity: Percentage of population who are Immigrants and Norwegian-born to immigrant 
parents. 
Income: Average gross income in a year. 
Density of general practitioner (GP): Number of GP per 10000 inhabitants. 
Population density: Number of population per km2. 
Living alone: Percentage of population who lives alone. 
Smoking: Percentage of population (16-74 years) who smoke daily. 
Unemployment rate: Percentage of population who are unemployed.  
Married person: Percentage of population (18+ years) who are married. 
Social assistance: Percentage of population (16-67 years) who receive social assistance. 
Age groups: In this study total population is divided into six groups that are age group 0-24, age 
group 25-34, age group 35-44, age group 45-69, age group 70-79, and age group 80+. Every 
group measured by the percentage of total population. This study used age group 0-24 as 
reference group. 
4.2 Empirical model: 
In this research we used a simple econometric model to examine the relationship between 
responsible factors and psychotropic drugs consumption. In other words, the model has been 
used to test the hypothesis whether these factors are responsible for regional variation of 
psychotropic drugs use or not.  
We defined a consumption function for psychotropic drugs use in Norway, which depended on 
average temperature, average precipitation rate, disability rate, level of education, ethnicity, 
average income level, density of general practitioner (GP), population density, living alone, 
15 
 
smoking habit, unemployment rate, married person, social assistance and different age groups 
(age group 0-24, age group 25-34, age group 35-44, age group 45-69, age group 70-79, age 
group 80+). Both supply side and demand side factors are included in our consumption function.  
In our study the counties considered as unit of analysis. The consumption function of 
psychotropic drugs use is following:  
DRit = ƒ(TEit, PRCit, DIit, EDit, EIit, Iit, GPDit, PDit, LAit, SMit, URit, MPit, SAit, AG2it, AG3it, AG4it, 
AG5
 it, AG6it, Ci) 
Where DRit is the psychotropic drugs use in county i and year t, TEit is the average temperature, 
PRit is the precipitation rate, DIit is the disability persons, EDit indicates the level of education, 
EIit is the ethnicity, Iit is the average income, GPDit is the density of general practitioner (GP), 
PDit is the population density, LAit is the people who living alone, SMit is the smoking habits, 
URit is the unemployment rate, MPit indicate the married person, SAit represent the persons who 
takes social assistance, AG1it represent the age group 0-24, AG2it represent the age group 25-34, 
AG3it represent the age group 35-44, AG4it represent the age group 45-69, AG5it represents the 
age group 70-79, AG6it represents the age group 80+ and Cit is the dummy variables for counties. 
In our study we used log linear model that are as follows: 
lnDRit = α + β1TEit +β2PRCit + β3DIit + β4EDit + β5EIit + β6Iit +β7GPDit + β8PDit + β9LAit + 
β10SMit + β11URit +β12MPit + β13SAit+ β14AG2it + β15AG3it +β16AG4it + β17AG5it + β18AG6it 
+∑  kCi + Uit 
Where C is the counties (where i = 1,2,………..,19.) and Uit is error term. Here ln() is the natural 
logarithm. 
To assess the models that deal with over time cross sectional data (panel data) literatures can 
provide us various types of econometric models, but the main two most useful and popular 
methods are random effect and fixed effect model.  Our data set contains relatively small number 
of time periods than cross sectional units that confirm us that we have panel data set and we can 
precede with fixed or random effect models. To choose the appropriate econometric model 
between fixed and random effect models we used the Hausman test.   
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4.3 The Hausman test: 
The Hausman specification test provides a clear idea which model should be used, random effect 
or fixed effect model. The main assumption of random effect model is that there is no significant 
relationship between time invariant variables with time variant explanatory variables that means 
independent variables and unobserved effects are not correlated. Hausman specification test 
identify whether the assumption is violated or not. If the assumption is true that no relationship 
between independent variables and unobserved effect, then the random effect estimator is more 
efficient than fixed effect estimator. On the other hand, if the assumption is violated random 
effect model provide inconsistence estimate of coefficient β and fixed effect model would be the 
best choice. 
Under null hypothesis, there is no correlation, Hausman specification test is a measure of the 
difference of two estimates. Hausman test statistics H is as follows: 
 H = (βˆRE - βˆFE)' [Var (βˆFE) - Var (βˆRE)]-1 (βˆRE - βˆFE)   
Where βˆFE is coefficient estimate of fixed effect model and βˆRE is coefficient estimate of 
random effect model. 
The Hausman test is a chi-square test and H is a distributed chi-square with (k-1) degrees of 
freedoms where K is number of regressors in the model.  If the P- value less than .05, we reject 
the null hypothesis that told us the two models are different and we have to run the fixed effect 
model. 
4.4 Fixed effect model:  
Fixed effect model consider the case that the unobservable explanatory (latent time invariant) 
variable are correlated with observable explanatory (latent time variant) while random effect 
model assume no relationship between time invariant and time variant independent variables. 
Fixed effect model provide unbiased estimate by controlling all time invariant explanatory 
variables that are correlated with time varying explanatory variables.     
Let we consider a panel data set where we have data for a dependent variable, Y and three 
independent (explanatory) variables, X1, X2, and X3 that are observable. Total time periods of this 
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data set are T and total units are N that shows N times T observations. By this data set we 
developed a relationship between dependent variable and independent variables that consists 
observable and unobservable explanatory variables. So the fixed effect model is: 
 Yit = β0 + β1Xit1 + β2Xit2 + β3Xit3 +uit 
Where i = 1, 2, …, N  and  t = 1, 2, …, t     
E (uit) = 0 and Var uit = σ2, that shows i.i.d. (independent random variables). 
In model, Yit shows the value of Y for the ith unit for the tth time period where Xit1, Xit1 and Xit1 
represent the value of X1, X2 and X3 for the ith unit for the tth time period respectively. Error tem 
µit shows the µfor the ith unit for the tth time period.  
The least squares dummy variable estimator: 
We can use least squares dummy variable estimator as fixed effect estimator. In that case we 
have to create dummy variables for the units. Here we use total N-1 dummies for N units. These 
dummy variables defined as follows: 
                                                       Dkit = 0       if k ≠i 
            Dkit= 1      if k = i 
We can include these dummy variables in our model as independent variables. Now the new 
model will be as follows: 
 Yit = β0 + β1Xit1 + β2Xit2 + β3Xit3 + α1D1it + α2D2it + … + αnDnit + uit 
Where, i = 1, 2, …, N  and  t = 1, 2, …, t     
That model follows that Ordinary Least Square (OLS) estimator.   
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5  Results 
5.1 Hausman test: 
This study conducted Hausman test to determine whether random effect or fixed effect model 
performed adequately for different drugs categories psychotropic, antidepressant, anxiolytics, 
and hypnotics and sedatives drugs separately. The Hausman test follows chi-square test and the 
value of chi-square tests are THausman= 783.96 for psychotropic drug, THausman= 590.14 for 
antidepressant drug, THausman= 245.41 for anxiolytics drug, and THausman= 217.83 for 
hypnoticsand sedatives drug. All of the results are significant (p < 0.05) and reject null 
hypothesis, there is no significant relationship between time invariant variables with time variant 
explanatory variables, it indicates the fixed effect model were preferred for this study. 
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Table 2: Parameter estimates for four fixed effect model of different psychotropic drugs use in Norway 
 
 
  Psychotropic  Antidepressant  Anxiolytics  Hypnotics and sedatives 
Coefficient S. error Coefficient S. error Coefficient S. error Coefficient S. error 
Temperature -0.0059 0.0021*** -0.0084 0.0025*** -0.0035 0.0034 0.0021 0.0026 
Precipitation 0.0037 0.0057 0.0113 0.0083 -0.0039 0.0112 -0.0026 0.0086 
Disability -0.0027 0.0017 0.0324 0.0082*** -0.0169 0.0111 -0.0323 0.0084*** 
Education 0.0151 0.0059** 0.0291 0.0082*** 0.0045 0.0111 -0.004 0.0084 
Ethnicity -0.0079 0.0031** 0.0029 0.0045 -0.025 0.0061*** -0.0119 0.0046** 
Income 0.0265 0.0184 0.0027 0.0256 0.0855 0.0347** 0.0359 0.0264 
GP density -0.0125 0.0069* 0.0079 0.0098 -0.0144 0.0133 -0.0241 0.0101** 
Population density 0.0005 0.0002** 0.0006 0.0003* 0.0011 0.0005** 0.0002 0.0003 
Smoking -0.00001 0.0011 0.0012 0.0017 -0.0021 0.0023 -0.0001 0.0017 
Unemployment rate -0.018 0.0041*** -0.0249 0.0060*** -0.0204 0.0082** -0.0085 0.0062 
Married -0.0004 0.0086 -0.0164 0.0119 0.0692 0.0161*** 0.0009 0.0123 
Social assistance 0.0321 0.0112*** 0.0307 0.0166* 0.0937 0.0225*** 0.0048 0.0171 
Living alone 0.0107 0.0075 0.0056 0.0103 0.0373 0.0139*** 0.0189 0.0106* 
Age group 25-34 -0.0031 0.0116 -0.0296 0.0167* 0.0342 0.0227 0.0079 0.0173 
Age group 35-44 0.0738 0.0175*** 0.0178 0.024 0.1548 0.0326*** 0.1468 0.0248*** 
Age group 45-69 0.0456 0.0098*** -0.0071 0.0142 0.0425 0.0193** 0.1007 0.0147*** 
Age group 70-79 0.07 0.0197*** 0.0689 0.0280** 0.0419 0.038 0.0779 0.0289*** 
Age group 80+ 0.1274 0.0328*** 0.0977 0.0478** 0.272 0.0649*** 0.1225 0.4938** 
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Table 3: Parameter estimates of different counties for four fixed effect model of different psychotropic drugs use in Norway 
R-squared value                   0.9964                                    0.9936                                       0.9917                                      0.9937 
Number of observations = 156; Level of significance: * p < 0.10, ** p < 0.05, *** p < 0.01. 
  Psychotropic  Antidepressant  Anxiolytics  Hypnotics and sedatives 
Coefficient S. error Coefficient S. error Coefficient S. error Coefficient S. error 
Akershus -0.0829 0.0819 -0.1163 0.129 -0.2297 0.1751 -0.0366 0.1333 
Aust-Agder 0.3444 0.0782*** 0.1739 0.1122 0.2418 0.1523 0.5522 0.1159*** 
Buskerud 0.0948 0.0412** 0.0603 0.0631 0.1723 0.0856** 0.0544 0.0652 
Finnmark -0.1018 0.0868 -0.3768 0.1254*** 0.7024 0.1702*** -0.1357 0.1296 
Hedmark -0.127 0.0246*** -0.0391 0.0365 -0.2179 0.0495*** -0.2395 0.0377*** 
Hordaland 0.1193 0.0509** 0.0769 0.0841 0.0432 0.1141 0.1812 0.0869** 
Møre og Romsdal -0.0581 0.0512 -0.1545 0.0807* -0.2074 0.1095* 0.1084 0.0833 
Nordland -0.0477 0.0398 -0.1789 0.0575*** 0.1848 0.0780** 0.0004 0.0594 
Nord-Trøndelag 0.0351 0.0492 0.0503 0.0736 -0.0851 0.0999 0.0723 0.076 
Oslo -0.4933 0.3451 -0.9107 0.5108* -1.0123 0.6932 0.0089 0.5278 
Rogaland 0.3568 0.1063*** 0.3409 0.1625** 0.0444 0.2205 0.4432 0.1679*** 
Sogn og Fjordane -0.1788 0.0573*** -0.0926 0.0922 -0.47 0.1251*** -0.2099 0.0953** 
Sør-Trøndelag -0.1114 0.0403*** -0.2966 0.0605*** 0.1356 0.0821 0.0396 0.0625 
Telemark 0.1657 0.0306*** -0.0095 0.0412 0.3397 0.0559*** 0.2329 0.0426*** 
Troms -0.1756 0.0524*** -0.4138 0.0757*** 0.4011 0.1027*** -0.1313 0.0782* 
Vest-Agder 0.3409 0.0909*** 0.0094 0.1312 0.2609 0.178 0.6632 0.1356*** 
Vestfold 0.0252 0.0389 -0.0977 0.0539* 0.0172 0.0733 0.1267 0.0558** 
Østfold 0.2651 0.0502*** 0.2664 0.0651*** 0.2551 0.0884*** 0.1461 0.0673** 
Constant 0.1041 0.8799 1.6392 1.2387 -6.9803 1.6811*** -2.2791 1.2799* 
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5.2 Fixed effect model: 
Estimated parameters of four different fixed effect models are summarized in Table 2 and 3.  
Table 2 contains the estimated parameters of all independent variables except regions while table 
3 includes the parameter estimates of different regions. There are no structural differences 
between four models and all are fixed effect model with same independent variables but only 
difference within four models are different dependent variables that are psychotropic drug, 
antidepressant drug, anxiolytics, and hypnotics and sedatives drug. 
In our study we used log linear model. To get the value in elasticity we multiplied the coefficient 
value by the average value of independent values*.  
The responsiveness of psychotropic and antidepressant drugs to the change of average 
temperature is negative and statistically significant (at 1 percent level) which shows the inverse 
relationship between drug use and average temperature, meaning that a one percent increase in 
average temperature will reduce 0.0325 and 0.0462 percent psychotropic and antidepressant drug 
use respectively. 
Disability has positive impact on antidepressant, and negative impact on hypnotics and sedatives 
drug use and both are statistically significant at 1% level. An increase of disable persons by one 
percentage point, on average, consumption of antidepressant drug will increase 0.3392% while it 
will decrease 0.3382% hypnotics and sedatives drug use. 
*Let, we have log linear function: 
lnY = a + b X → 	 

		
 = b → 		
		
. 


= b  
Obviously, we have to multiply both sides by X to get an elasticity value. 
		
		
. 


= b X 
Here we evaluated X by the mean value, X – bar. 
Let, bx̅ =  
So, 1% increase in X will increase Y by %. 
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Higher level of education is positively associated with psychotropic and antidepressant drug use 
which are statically significant at 5% and 1% respectively. If level of education will increase one 
percent it increases the psychotropic drug use by 1.0309% and antidepressant drug use by 
1.9868%. 
Percentage of immigrant (non-Norwegian ethnic groups) people has a negative and significant 
effect on psychotropic, anxiolytics, and hypnotics and sedatives drug use. Result shows that, an 
increase in immigrant population by 1%, it will reduce the consumption of psychotropic, 
anxiolytics, and hypnotics and sedatives drugs by 0.0623%, 0.1973%, and 0.0939% and these 
effects are statistically significant at 5%, 1%, and 5%, respectively.  
The sign of the coefficient of average gross income is positive that shows a positive relationship 
between average gross income and anxiolytics drug consumption. The level of significance of 
coefficient is 5%. A 1% increases in income, on average, increase the consumption of anxiolytics 
drug 0.2688 percentage point. 
GP density is negatively associated with psychotropic, and hypnotics and sedatives drug use 
which confirms the inverse relationship. Study presents that, if GP density increases 1% 
consumption of psychotropic, and hypnotics and sedatives drugs will decrease 0.1079% and 
0.2080% that are statistically significant at 10% and 5% level respectively. 
The population density has a positive and significant effect on psychotropic, antidepressant, and 
anxiolytics drugs consumption. A 1% increase in population density is associated with an 
increase in psychotropic, antidepressant, and anxiolytics drugs consumption by 0.0448%, 
0.0538% and 0.0987% with 5%, 10% and 5% level of significance respectively. 
The coefficients of unemployment are negative that shows the inverse relationship between 
unemployment rate and psychotropic, antidepressant, and anxiolytics drugs consumption and this 
effect is highly significant at 1% level of significance for psychotropic, and antidepressant drugs, 
and at 5% level for anxiolytics drug, which confirmed that, one percentage increase in 
unemployment rate will decrease the psychotropic, antidepressant, and anxiolytics drug by 
0.0484%, 0.0669%, and 0.0546%, respectively.  
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Anxiolytics drug consumption responses positively and significantly to the change of percentage 
of married persons. This responsiveness is statistically significant at 1% level and it implies a 1% 
increase in percentage of married person will increase 3.3739% consumption of anxiolytics drug. 
Consumption of anxiolytics, and hypnotics and sedatives drugs response positively to change of 
the percentage of individual who lived alone and it is significant at 1% and 10% level 
respectively which shows one percentage change in alone persons will increase anxiolytics, and 
hypnotics and sedatives drugs consumption by 0.6210% and 0.3147%, respectively.  
This study also found a positive and significant relation between percentage of population who 
receive social assistance and psychotropic, antidepressant, and anxiolytics drug consumption. 
Consumption of these three drugs will increase by 0.1017%, 0.0973%, and 0.2969%, 
respectively with the increase in one percentage of individual who are taking social assistance.  
The effect of age on different drugs consumption was captured by six different age groups that 
are 0-24, 25-34, 35-44, 45-69, 70-79, and 80+ where age group 0-24 used as reference group. We 
observed an inverse relationship between age group 25-34 and antidepressant drug consumption 
which is significant at 10% significance level. It shows that 1% increase in percentage of 
individual aged 25-34, with respect to percentage of individual aged 0-24, will reduce 
antidepressant drug consumption by 0.3696%. Age group 35-44 is positively associated with 
psychotropic, anxiolytics, and hypnotics and sedatives drugs consumption at 1% significant 
level. An increase of individual aged 35-44 by one percentage point, on average, will increase 
consumption of psychotropic, anxiolytics, hypnotics and sedatives drugs by 1.0798%, 2.2659%, 
and 2.1479% respectively. Age group 45-69 also has a significant positive impact on 
psychotropic, anxiolytics, and hypnotics and sedatives drugs consumption at 1%, 5%, and 1% 
level of significance. Results shows 1% positive change in age group 45-69 will positively 
change the consumption of psychotropic, anxiolytics, and hypnotics and sedatives drugs by 
1.3581%, 1.2658%, and 2.9991% respectively. The estimated coefficient indicates significant 
positive relationship between age group 70-79 and psychotropic, antidepressant, and hypnotics 
and sedatives drugs at 1% significant level which confirms that one percentage increased 
percentage of individual aged 70-79 is predicted, on average, to increase psychotropic, 
antidepressant, and hypnotics and sedatives drugs consumption by 0.4482%, 0.4411%, and 
0.4987% respectively. The extreme age group 80+ is strongly associated with all types of 
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psychotropic drugs (anxiolytics, antidepressant, hypnotics and sedatives) individually and 
aggregately. From the regression results, 1% increase in percentage of individual aged 80+ will 
increase psychotropic, antidepressant, anxiolytics, and hypnotics and sedatives drugs 
consumption by 0.6036%, 0.4629%, 1.2887%, and 0.5804% and these results are significant at 
1%, 5%, 1%, and 5% level respectively. 
This study consider the Oppland as reference county according to geographical and socio 
demographical situation and shows the effect of other 18 counties, with respect to reference 
county, on different psychotropic drugs consumption. Psychotropic drug is positively related 
with counties, Aust-Agder, Buskerud, Hordaland, Rogaland, Telemark, Vest-Agder, and Østfold 
where Rogaland is the highest consumed county by 36% more consumption than Oppland. Other 
counties Aust-Agder, Vest-Agder, Østfold, Telemark, Hordaland, and Buskerud consumed 34%, 
34%, 27%, 17%, 12%, and 9% more than Oppland respectively. On the other hand psychotropic 
drug is negatively related with counties Sør-Trøndelag, Hedmark, Troms, and Sogn og Fjordane 
where these four counties consumed 12%, 13%, 18%, and 18% less than Oppland respectively. 
Antidepressant drug consumption is inversely and significantly associated with different counties 
that are Finmark, Møre og Romsdal, Nordland, Oslo, Sør-Trøndelag, Troms, Vestfold where 
positively and significantly associated with counties, Rogaland, and Østfold. On the other hand 
Buskerud, Finmark, Nordland, Telemark, Troms, and Østfold counties have positive impact and 
Hedmark, Møre og Romsdal, and Song og Fjordane counties have negative impact on anxiolytics 
drug consumption. The responsiveness of hypnotics and sedatives drug consumption to the 
counties Aust-Agder, Hordaland, Rogaland, Telemark, Vest-Agder, Vestfold, and Østfold are 
positive while counties Hedmark, Song og Fjordane, and Troms are negative. 
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6  Discussion 
The investigation of regional variation in prescription of psychotropic drugs use may take an 
important role to formulate efficient drugs use in an effective government intervention. By the 
use of econometric approach this study provided that there are huge differences in psychotropic 
drugs use in different counties in Norway and these differences mainly occurred because of 
different characteristics of different counties (demographical and geographical) and different 
socioeconomic situations.  
Temperature: There are no comparable research studies that deal with temperature and 
psychotropic drugs to find out the impact of temperature on the use of psychotropic drugs. 
Higher temperature will reduce antidepressant drug use and finally it also reduces psychotropic 
drugs use. Norway is a country where average temperature is very low compares to others 
countries in Europe and rest of the world. In 2011 average temperature was 6.03 degree Celsius 
in Norway. This low temperature may cause of depression in large number of people. Our study 
suggests that higher temperature can reduce depression that decreases the use of antidepressant 
drugs. Our study also showed that psychotropic drugs use decreases with the higher temperature 
and vise verse.   
Age: Most of the previous studies found a positive association between age and psychotropic 
drugs use and this study replicate the findings of previous studies, showing the prevalence of 
psychotropic drugs use is significantly increased with higher age group (Bocquier et al. 2008; 
Paulose-Ram R. et al. 2004; Isacson and Haglund 1988; Rojas et al. 2005). Mental health status 
declines with age and older persons are more vulnerable to psychological and neurological 
disorder than younger. As a result they need more health care which is the main reason that 
works behind the positive association between higher age and psychotropic drugs use. Within 
three psychotropic drugs, hypnotic (HY) is strongly associated with increasing age than other 
drugs, which is supported by the several previous studies (Kjosavik et al. 2009; Kassam and 
Patten, 2006; Blennow et al. 1994; Wells et al.1985; Hollingworth and Siskind 2010).  Like other 
studies this study also showed higher association between Antidepressant use and old age 
persons (Demyttenaere et al. 2008; Kjosavik et al. 2009; Hansen et al. 2004) but Kaplan et al. 
(1987) did not find any association of age and symptoms of depression. Our study also showed a 
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positive relationship between higher age and higher use of anxiolytics drug (Neutel 2005; 
Demyttenaere et al. 2008; Wellset al.1985; Hollingworth and Siskind 2010).  
 
Income: Reviewed of previous literatures cannot permit us to conclude about the connection of 
level of income and psychotropic drugs use. Our study did not find any statistically significant 
association of psychotropic drug use with income that supported by Lorant et al. (2007) and 
Rojas et al. (2005). But according to Lesen et al. (2010)   psychotropic drug use will increase 
with lower income. Several studies from low and middle income countries also showed that 
lower income significantly increases the common mental disorders (psychotropic syndrome) 
(Ludermir and Lewis 2001; Patel et al. 2006). Our study also showed that income has no 
significant effect on antidepressant and hypnotic dugs (Wells et al. 1985). But Kassam and 
Patten (2006) demonstrated that hypnotic use will increase with lower income than higher 
income as like Ohayon (1996) and Paulose-Ram et al. (2004). In contrary Bocquier et al. (2008) 
confirmed the positive association between higher income and hypnotic drug use. Kaplan et al. 
(1987) showed that income is not associated with symptoms of depression while higher income 
will decrease the antidepressant use (Mumford et al. 1996; Hansen et al. 2004). From our study, 
consumption of anxiolytics increased with higher income that is supported by Bocquier et al. 
2008 and Wells et al.1985. The main reason is that higher income creates higher health care 
demand. As a result people consume more anxiolytics when income increases. In contrary some 
studies concluded that lower income increases anxiolytics use (Ohayon 1996; Paulose-Ram et al. 
2004; Mumford et al. 1996). 
Education: The relationship between level of education and psychotropic drugs use is not 
clear according to previous literatures while some studies showed positive association of higher 
education and psychotropic drugs use, other studies found negative association. After the 
investigation of the effect of higher education on psychotropic drugs, this study concludes the 
higher use of aggregate psychotropic drugs with the higher education (Andrews et al. 2001). 
Higher educated persons are more conscious about their health than lower educated persons and 
they always tried to maintain a good health status. In a developed country where health is one of 
the core prioritized sector it is easier to take health service when any persons feel to need. 
Norway is one of the highly developed country and most of the higher educated persons live in a 
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busy life by engaging different works which are the main causes of high consumption of 
antidepressant and aggregate psychotropic drugs among the higher educated persons. Studies 
from low and middle income countries undoubtedly showed the negative association between 
common mental disorder (psychotropic) and higher education (Ludermir and Lewis 2001; Araya 
et al. 2001; Patel et al. 2006). Skurtveit et al. (2005) also showed a negative relationship between 
higher education and psychotropic drug use while Rojas et al. (2005) did not find any statistical 
significant relationship between psychotropic drugs and education. Our study also confirmed the 
use of antidepressant drug is higher among the higher educated persons which is consistent with 
previous study (Blumenthal and Endicott 1996). Some studies mentioned that lower education is 
one of the main causes of higher antidepressant drug use (Paulose-Ram et al. 2004; Kaplan et al. 
1987; Mumford et al. 1996; Demyttenaere et al. 2008) .We did not find any association between 
education and anxiolytics use. But Neutel (2005) showed the relation of higher education, higher 
anxiolytics use while other studies (Paulose-Ram et al. 2004; Demyttenaere et al. 2008; 
Mumford et al. 1996; Wells et al.1985) showed opposite result that is higher education lower 
prevalence of anxiolytics. In the case of hypnotic use our study did not report any statistical 
significant association with education which is supported by Wells et al. (1985). But study by 
Neutel (2005) showed the relation of higher education, higher hypnotic use while other studies 
(Paulose-Ram et al. 2004; Kassam and Patten, 2006) showed opposite result, higher education 
lower prevalence of hypnotic. 
Unemployment: Perhaps surprisingly, we found negative association between unemployment 
rate and psychotropic drugs, and separately antidepressant and anxiolytics drugs but we did not 
find any significant association between hypnotic and unemployment rate. The main cause of 
this kind of result is lower unemployment rate in Norway. In 2011, average unemployment rate 
was only 2.67 percent that are quit low and most of the unemployment was temporary 
unemployment in Norway which can provide a break from hard work and works as relaxation 
period. Most of the studies about psychotropic, antidepressant, anxiolytics, and hypnotic drugs 
confirmed the positive association with unemployed persons (Araya et al. 2001; Bocquier et al. 
2008; Magrini et al. 1996; Demyttenaere et al. 2008; Blennow et al. 1994; D’Incau et al. 2011; 
Hansen et al. 2004). But Rojas et al. (2005) and Lorant et al. (2007) did not find any statistical 
significant relationship between employment status and psychotropic, and antidepressant drugs. 
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According to Weich and Lewis (1998), the common onset of common mental disorder is 
financial strain and employment status is not working as the onset of common mental problem 
but if any common mental problem exists because of financial strain, unemployment situation 
can increased the duration of episodes. 
Ethnicity: We are not able to conclude the effect of ethnicity on the use of psychotropic drugs 
from the results of previous studies. In our study we found immigrant person (mostly non-white) 
has less prevalence of psychotropic drug use (Paulose-Ram et al. 2004; Sleath et al. 1998). In 
Norway, most of the (over 50%) immigrants came from outside of Europe, mainly from Asia and 
Africa, where family members tried to live together compared to European countries and they 
tried to share their problem with family members which works against the use of different 
psychotropic drugs. Opposite result came from a British study (Jenkins et al. 1997) based on 
household survey. We did not find any statistical significant relationship between ethnicity and 
antidepressant use which supported by Kaplan et al. (1987). On the other hand Paulose-Ram et 
al. (2004) and Brown et al. (1995) showed a positive association of antidepressant use with white 
ethnic. In our study we confirmed that immigrant persons are less associated with anxiolytics, 
and hypnotic drugs use than others (Paulose-Ram et al. 2004; Neutel 2005; Wells et al.1985; 
Blazer et al. 2000; Swartz et al. 1991). 
Disability: Consistent with previous studies, our study confirmed that antidepressant use is 
strongly associated with physical disability condition (Kaplan et al. 1987; Sihvo et al. 2008; 
Hansen et al. 2004; Parikh et al. 1999). The prevalence of depression is high among the disable 
persons because of their physical condition. We also found a higher prevalence of hypnotic drug 
use among the disable persons where Blennow et al. (1994) showed the opposite result. In 
reference to anxiolytics use we did not find any statistical significant relationship between 
disability condition and anxiolytics use. 
GP density: A few studies have demonstrated the relationship between GP density and 
psychotropic drugs.  The results of Kisely et al. (2000) verified the negative effect of GP density 
on hypnotics use in a situation of ‘client centered’ system (It is a system where each patient has 
an identified GP) which is the same as we found from our study. We did not find any statistical 
significant association between prevalence of antidepressant, and anxiolytics use and GP density 
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(Bocquier et al. 2008), while a negative association between GP density and aggregate 
psychotropic drug use confirmed by our study. The main reason of this negative association is 
that drugs prescription was substituted by the doctor consultations. In an area where GP density 
is high, GP compete to each other for patients. In that situation GP can provide more 
consultations instead of drug prescription which decreases the consumption of psychotropic 
drugs where GP density is high. 
Population density: There is no previous research which examined the effect of population 
density on the use of psychotropic drugs use. We have used population density as a responsible 
factor for psychotropic drugs use and found positive association of psychotropic drugs use with 
the population density. Higher density of population will increase the use of antidepressant, 
anxiolytics, and aggregate psychotropic drugs use. The main cause of high risk of mental 
disorder is social stress that is likely to occur as a direct consequence of higher population 
density. People live in crowded area have higher social stress, as a result they consume more 
psychotropic drugs. But we did not find any statistically significant relation between population 
density and hypnotics use. 
Smoking: Our research has examined the effect of smoking habits on the use of psychotropic 
drugs use and did not find any statistical significant relationship. But the some of the previous 
studies have confirmed the positive effect of smoking habits on the use of antidepressant, 
anxiolytics, hypnotics, and aggregate psychotropic drugs use (Neutel 2005; Tomasson et al. 
2007; Skurtveit et al. 2005). 
Married person: Reviewed of previous studies have demonstrated contradictory results 
about the association of psychotropic drugs use with marital status. Our results showed no 
significant association between aggregate psychotropic drug use and marital status (Rojas et al. 
2005). But Lesen et al. (2010) showed that, married persons have lower risk of psychotropic 
drugs use while opposite results came from Patel et al. (2006). Most of the studies confirmed the 
significant decreasing antidepressant drug use in married persons than single or others (Lorant et 
al. 2007; Jenkins et al. 1997; Hansen et al. 2004) whereas Mumford et al. (1996) found 
increasing antidepressant use in married persons. But in our study we did not find any significant 
results about the relation of antidepressant drug use and marital status (Kaplan et al. 1987). In 
reference of anxiolytics, our study showed a positive association between anxiolytics use and 
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married persons (Mumford et al. 1996). The main reason is the high divorce and separation rate 
in Norway. In 2012, 24346 marriages have constructed while 11094 couples have separated and 
9929 marriages have dissolved by divorce (SSB). High number of divorce and separation can 
create an anxiety among the married persons. A British study (Jenkins et al. 1997) based on 
household survey and a Canadian study (Kassamand Patten 2006) showed that married persons 
have lower prevalence of anxiolytics use where Wells et al. (1985) found no association between 
marital status and anxiolytics use. From our study marital status is not associated with hypnotics 
use (Wells et al.1985) where Kassamand Patten (2006) confirmed the negative association 
between hypnotics use and married persons. 
Social assistance: To the best of our knowledge, there is no comparable study to examine the 
effect of social assistance on psychotropic drugs use. We have used social assistance as a 
predictor of psychotropic drugs use and found a strong effect on drugs consumption. Getting 
social assistance is positively associated with antidepressant, anxiolytics, and aggregate 
psychotropic drugs use which confirmed us that prevalence of antidepressant, anxiolytics, and 
aggregate psychotropic drugs use is higher among the persons who are dependent on government 
social support. Government provides financial support to the poor people but this support is very 
limited and it is the only income source of these people. In that situation people can face 
different mental disorders specially depression and anxiety. As a result prevalence of 
psychotropic drugs consumption is higher among the people who are dependent on government 
support. In the case of hypnotics use social assistance has no significant effect. 
 
Living alone: Prevalence of anxiolytics and hypnotics drugs use is high among the persons 
who are isolated from their family and live alone. Living with family members is an important 
thing for mental health and it can help to keep good mental health. When man lives with his 
family members he can share his any depressive situation with others and can get help and feel 
secure. On the other hand, when man lives alone he feels insecure and he can be fall in a mental 
problem with small things. Our results are supported by Demyttenaere et al. (2008) and D’Incau 
et al. (2011). In reference of antidepressant and aggregate psychotropic drugs use our study is not 
able to provide any statistical significant results. But the several studies (Kaplan et al. 1987; 
Demyttenaere et al. 2008; D’Incau et al. 2011) have good results to show positive association 
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between social isolation (live alone) and depressive syndrome that increase the use of 
antidepressant drug. 
To estimate the regional variation of psychotropic drugs use in Norway we have considered the 
county `Oppland` as our reference county. In Norway there are huge differences between 
counties in reference of geographic, demographic, and socioeconomic situation. We have used 
graphical information system to show the results from fixed effect model about the variation of 
psychotropic drugs use between different counties.   
To best our knowledge there is no previous studies that deal with the regional variation in 
prescription of psychotropic drugs use by using econometric analysis and graphical information 
system. This study is a new addition in this sector. We have illustrated some graphs to show the 
regional variation in prescription of aggregate psychotropic drugs, antidepressant, anxiolytics, 
and hypnotics drugs. 
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Figure 6.1: Regional variation in prescription of aggregate psychotropic drug  
 
 
 
Figure 6.1 shows the regional variation in prescription of aggregate psychotropic drug in Norway 
in reference of Oppland county. From figure there are huge differences between counties. We 
can see that seven counties, Aust-Agder, Buskerud, Hordaland, Rogaland, Telemark, Vest-
Agder, and Østfold, have significantly positive effect on aggregate psychotropic drug use than 
Oppland and all of the seven counties are in south part than Oppland. On the other hand, most of 
the counties that are situated north side by Oppland have negative effect on aggregate 
psychotropic drug use but only four counties (Hedmark, Song og Fjordane, Sør-Trøndelag, and 
Troms) have significant negative effect. This kind of result gives a clear message to us about 
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regional variation in prescription of aggregate psychotropic drug use. If we follow the color of 
counties in figure 6.1, where blue shows the reference county, red shows the significant positive 
effect, yellow shows the significant negative effect, and green shows the insignificant counties, 
we can easily see that there are clear differences between southern and northern counties by 
Oppland according to aggregate psychotropic drug use. 
Figure 6.2: Regional variation in prescription of aggregate psychotropic drug within 
southern part by Oppland county in Norway 
 
  
Figure 6.2 represents the southern part of Norway by Oppland County. All of the colors (except 
green) showed the positive effect of psychotropic drug use but in different levels. Buskerud have 
used 9% more psychotropic drug use than Oppland while Hordaland, Telemark, and Østfold 
have use 12%, 17%, and 27% more respectively. The second highest psychotropic drug used by 
Aust-Agder and Vest-Agder (34% more than Oppland) follows by highest user Rogaland (36% 
more than Oppland). We can conclude that, the more we move towards the southern part by 
Oppland, the more the psychotropic drug use increased. 
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Figure 6.3: Regional variation in prescription of aggregate psychotropic drug within other 
parts (except southern part) of Norway. 
  
Figure 6.3 shows the other parts of Norway that are not showed in figure 6.2. Blue color 
represents the reference county Oppland and green color represents the counties which have the 
insignificant effect. Other three colors show the negative effect on the use of psychotropic drug 
in different magnitudes. Troms and Sogn og Fjordane used almost 18% less psychotropic drug 
than Oppland which confirm the lowest consumption of psychotropic drug in Norway. Hedmark 
consumed 13% less than Oppland while Sør-Trøndelag consumed 12% less than Oppland 
county. 
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Figure 7: Regional variation in prescription of antidepressant drug 
  
 
We demonstrated the variation in prescription of antidepressant drug use between different 
counties based on Oppland county in Norway in figure 7. Reference county, those have 
significant positive effect, those have significant negative effect, and those have no significant 
effect are marked by the four different color, blue, red, yellow, green, respectively. From the 
figure 7 we conclude that counties north of Oppland have significantly less antidepressant use 
than southern part. 
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Figure 8: Regional variation in prescription of hypnotics and sedatives drug 
  
Southern part has a strong significant positive effect on hypnotics and sedatives drug use in 
Norway. Most of the counties are from southern part (Aust-Agder, Hordaland, Rogaland, 
Telemark, Vest-Agder, Vestfold, and Østfold except Buskerud) by Oppland are significantly and 
positively associated with hypnotics use and colored by the red in figure 8. We also noticed that 
most of the northern counties by Oppland are statistically insignificant (colored by green) while 
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three counties (Hedmark, Song og Fjordane, and Troms) have significant negative effect on 
hypnotics and sedatives use (colored by yellow).   
Figure 9: Regional variation in prescription of anxiolytics drug 
  
 
 
We found a little bit opposite results in the case of anxiolytics drug use. Three northern counties 
of Norway, Finmark, Troms, and Nordland, have significant positive effect on anxiolytics use 
with other three southern counties, Buskerud, Telemark, and Østfold (marked by red color). On 
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the other hand shaded by the yellow color three counties, Hedmark, Møre og Romsdal, and Song 
og Fjordane, showed inverse relationship with anxiolytics drug use. 
If we consider figure 7, 8, and 9, we can see that they provided different results to us and we 
cannot conclude a south north differences but if we take aggregate of psychotropic drugs (total of 
antidepressant, anxiolytics and hypnotics) (figure 6.1) we conclude a north south difference in 
drug use. The main cause of these different results is substitution between these three drugs.  
In many cases physician recommend antidepressant instead of anxiolytics, and hypnotics for 
anxiety disorders (Balwin et al. 2005; NICE 2004; Kjosavik 2012) and sleeping disorders 
(Kjosavik 2012) respectively. According to Gardarsdottir et al. (2007) and Henriksson et al. 
(2003), symptom of depression is not only factor to use antidepressant, other factors, anxiety, 
sleeping disorder, also responsible for this. They showed total 45-66% antidepressant have used 
for depression symptoms where 14-17% for anxiety and 5-9% for sleeping disorder. One 
Canadian study Patten et al. (2007) showed that physician prescribe almost one third of 
antidepressant for other reason than depression where Beck et al. (2005) showed 40%. Several 
studies (Melartin et al. 2005; NICE 2007; American Psychiatric Association 2000) mentioned 
that large number of antidepressant use terminated within short period whereas Sihvoetal (2008) 
mention that, the short term user of antidepressant are mainly older than 65 years and sleeping 
disturbances are the main cause of antidepressant use of them. Other studies (Walsh 2004; 
Roberts et al. 2000; Ballenger et al. 1999) also found quite frequently use of antidepressant for 
anxiety and sleeping disorders. In reference of WHO collaborating center for drug statistics 
methodology, benzodiazepines (N05BA) is the main drug in anxiolytics but it also more usable 
for sleeping disorders. 
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7  Conclusion and policy recommendation 
To best our knowledge, this is the first study to explore the regional variation in prescription of 
psychotropic drugs use in Norway. The main objective of this study was to investigate the 
change in prescription of different psychotropic drugs in different counties in response to change 
in selective explanatory variables, and counties.  By using data from 19 counties over the 8 year 
periods from 2004-2011, we used a simple fixed effect model to analyze the regional variation in 
prescription of different psychotropic drugs use. We used consumption of different psychotropic 
drugs, antidepressant, anxiolytics, hypnotics and sedatives, and aggregate of these three drugs as 
psychotropic drug, in DDD per 1000 inhabitants per day (DID) as dependent variables and some 
selective independent variables, temperature, precipitation, disability, level of education, 
ethnicity, income, density of general practitioner (GP), population density, living alone, 
smoking, unemployment rate, married person, social assistance, different age groups, and 
different counties. By using same set of explanatory variables we played four regression analyses 
for four types of drugs. 
 In the first model we used consumption of aggregate of three drugs (as psychotropic drug) as 
dependent variable and found positive influenced by higher education, population density, taking 
social assistance, age group 35-44, age group 45-69, age group 70-79, and age group 80+ and 
negatively related with higher temperature, non-Norwegian ethnicity, GP density, and 
unemployment rate. We estimated second, third, and fourth model by using consumption of 
antidepressant, anxiolytics, and hypnotics and sedatives drug as dependent variables 
respectively. We found positive association of disable persons, higher education, population 
density, taking social assistance, age group 70-79, and age group 80+ and negative association of 
higher temperature, unemployment rate, and age group 25-34 with the consumption of 
antidepressant drug whereas consumption of anxiolytics is positively associated with higher 
income, population density, married persons, receiving social assistance, living alone, age group 
35-44, age group 45-69, and age group 80+ and negatively associated with non-Norwegian 
ethnicity, and unemployment rate. On the other hand, consumption of hypnotics and sedatives 
drug use has positive relationship with persons who lived alone, age group 35-44, age group 45-
69, age group 70-79, and age group 80+ and negative relationship with disable persons, non-
Norwegian ethnicity and GP density. 
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To demonstrate the regional effect on consumption of different psychotropic drugs we used 
geographical information system (GIS) as a way of explanation and Oppland as reference 
county. In the case of psychotropic drug (aggregate of three drugs) consumption, we found a 
clear north south variation by Oppland county. Southern part by Oppland has positive effect on 
the consumption of psychotropic drug use despite northern part by Oppland has negative or 
insignificant effect which permit to conclude that southern part by Oppland consume more 
psychotropic drug than northern part by Oppland in Norway. Moreover when we go through the 
southern part from Oppland the effect of counties on the consumption of psychotropic drug 
increased and finally Aust-Agder and Vest-Agder consumed second highest (34% more than 
Oppland) psychotropic drug after the highest consumed by Rogaland county (36% more than 
Oppland) .       
This study provides a clear message to the government how will be the government intervention 
to formulate efficient psychotropic drug distribution across the counties in Norway. The southern 
part by Oppland consumes more psychotropic drugs than northern part which must be considered 
by government when they will take any intervention.  
Limitations of this study:  
This study included only the General practitioner (GP) and excluded the specialist doctors 
because of insufficient data and we did not include the drugs bought from illegal black markets 
and legal abroad markets. Our main data source NorPD excluded almost 1% prescriptions due to 
missing data of some variables. This study did not consider patient’s compliance as it is 
unknown and used only dispensed prescriptions by the GP as a proxy of drugs consumptions by 
patients. 
 
 
 
 
 
 
41 
 
References: 
American Psychiatric Association, 2000. Practice guideline for the treatment of patients with 
major depressive disorder. Am. J. Psychiatry 57 (suppl 4), 1–45. Online access: www.apa.org 
 
Andrews, G., Issakidis, C., Carter, G., 2001. Shortfall in mental health service utilisation. Br. J. 
Psychiatry, 179: 417–425. 
 
Araya, R., Rojas, G., Fritsch, R., Acuna, J., & Lewis, G., 2001. Common mental disorders in 
Santiago, Chile: prevalence and socio-demographic correlates. British Journal of Psychiatry, 
178: 228-233. 
 
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den 
Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., Wittchen, H.-U., 2005. Evidence-based 
guidelines for the pharmacological treatment of anxiety disorders: recommendations from the 
British Association for Psychopharmacology. Journal of Psychopharmacology, 19 (6): 567–596. 
 
Ballenger, J. C., Davidson, J. R., Lecrubier, Y., Nutt, D. J., Goldberg, D., Magruder, K. M., 
Schulberg, H. C., Tylee, A., Wittchen, H. U., 1999. Consensus statement on the primary care 
management of depression from the International Consensus Group on Depression and Anxiety. 
Journal of Clinical Psychiatry, 60 (Suppl 7): 54–61. 
 
Beck, C. A., Patten, S. B., Williams, J. V. A., Wang, J. L., Currie, S. R., Maxwell, C. J., El-
Guebaly, N., 2005. Antidepressant utilization in Canada. Soc. Psychiatry Epidemiol, 40: 799–
807. 
 
Blazer, D., Hybels, C., Simonsick, E., Hanlon, J. T., 2000. Sedative, hypnotic, and antianxiety 
medication use in an aging cohort over ten years: A racial comparison. Journal of the American 
Geriatrics Society, 48:1073-1079. 
 
Blennow, G., Romelsjö, A., Leifman, H., Leifman, A., Karlsson, G., 1994. Sedatives and 
hypnotics in Stockholm - Social factors and kinds of use. American Journal of Public Health, 
84:242-246. 
 
Blumenthal, R., Endicott, J., 1996. Barriers to seeking treatment for major depression. 
Depression and Anxiety, 4: 273–278 
 
Bocquier, A., Bezzou, K., Nauleau, N., Verger, P., 2008. Dispensing of anxiolytics and 
hypnotics in southeastern France: Demographic factors and determinants of geographic 
variations. Fundamental & clinical Pharmacology, 22(3): 323-333. 
 
Brown, S. L., Salive, M. E., Guralnik, J. M., Pahor, M., Chapman, D. P. and Blazer, D., 1995. 
Antidepressant use in the elderly: Association with demo graphic characteristics, health-related 
factors, and healthcare utilization. Journal of Clinical Epidemiology, 48: 445-453. 
 
42 
 
Colman, I., Croudace, T. J., Wadsworth, M. E. J., Jones. P. B., 2008. Factors associated with 
antidepressant, anxiolytic and hypnotic use over 17 years in a national cohort. Journal of 
affective disorders, Vol. 110, Issue 3: 234-240. 
D’Incau, P., Barbui, C., Tubini, J., Conforti, A., 2011. Stressful life events and social health 
factors in women using anxiolytics and antidepressants: An Italian observational study in 
community pharmacies. Gender medicine, V.8: N.2. 
 
Demyttenaere, K., Bonnewyn, A., Bruffaerts, R., Girolamo, G. D., Gasquet, I., Kovess, V., Haro, 
J. M. & Alonso, J., 2008. Clinical factors influencing the prescription of antidepressants and 
benzodiazepines: Results from the European study of the epidemiology of mental disorders 
(ESEMeD). Journal of Affective Disorders, 110:84-93. 
Gardarsdottir, H., Heerdink, E. R., Dijk van, L., Egberts, A. C. G., 2007. Indications for 
antidepressant drug prescribing in general practice in the Netherlands. Journal of Affective 
Disorders, 98:109–115. 
 
Hansen, D. G., Søndergaard, J., Vach, W., Gram, L. F., Rosholm, J. U., Mortensen, P. B., 
Kragstrup, J., 2004. Socio-economic inequalities in first-time use of antidepressants: A 
population-based study. Eur J Clin Pharmacol, 60: 51–55. 
 
Hausken, A., M., 2010. Epidemiology of anxiolytic, and hypnotic drug use in the general 
population in Norway. Norwegian Institute of Public Health. 
 
Henriksson, S., Boethius, G., Håkansson, J., Isacsson, G., 2003. Indications for and outcome of 
antidepressant medication in a population: a prescription database and medical record study, in 
Jämtland county, Sweden, 1995. Acta Psychiatrica Scandinavica, 108: 427–431. 
 
Hollingworth, S. A., and Siskind, D. J., 2010. Anxiolytic, hypnotic and sedative medication use 
in Australia. Pharmaco epidemiology and drug safety, 19: 280–288. 
 
Hutchinson, J. M., Patrick, D. M., Marra, F., Ng, H., Bowie, W. R., Heule, L., Muscat, M. & 
Monnet, D. L., 2004. Measurement of antibiotic consumption: A practical guide to the use of the 
Anatomical Therapeutic Chemical classification and Defined Daily Dose system methodology in 
Canada. Can J Infect Dis., 15(1): 29-35. 
 
Isacson, D. and Haglund, B., 1988. Psychotropic drug use in a Swedish community – The 
importance of demographic and socioeconomic factors. Sot. Sci. Med., Vol. 26, No. 4: 477-483. 
 
Jenkins, R., Lewis, G., Bebbington, P., Brugha, T., Farrell, M., Gill, B. and Meltzer H., 1997. 
The National Psychiatric Morbidity Surveys of Great Britain - initial findings from the 
Household Survey. Psychological Medicine, 27:775-789. 
43 
 
Kalpan, G. A., Roberts, R. E., Camacho, T. C., Coyne, J. C., 1987. Psychosocial predictors of 
depression: Prospective evidence from the human population laboratory studies. American 
journal of epidemiology, Vol. 125, No. 2. 
 
Kassam, A. & Patten, S. B., 2006. Hypnotic use in a population-based sample of over thirty-five 
thousand interviewed Canadians. Population Health Metrics, 4:15. 
Kjosavik, S. R., Ruths, S., Hunskaar, S., 2009. Psychotropic drug use in the Norwegian general 
population in 2005: data from the Norwegian Prescription Database. Pharmaco epidemiology 
and drug safety, 18:572–578. 
 
Kisely, S., Linden, M., Bellantuono, C., Simon, G. & Jones, J., 2000.Why are patients prescribed 
psychotropic drugs by general practitioners? Results of an international study. Psychological 
Medicine, 30: 1217–1225. 
 
Lesen, E., Andersson, K., Petzold, M., Carlsten, A., 2010. Socioeconomic determinants of 
psychotropic drug utilization among elderly: a national population-based cross-sectional study. 
BMC Public Health, 10:118. 
 
Lorant, V., Croux, C., Weich, S., Deliege, D., Mackenbach, J., Ansseau, M., 2007. Depression 
and socio-economic risk factors: 7-year longitudinal population study. The British Journal of 
Psychiatry, 190:293-298. 
 
Ludermir, A. B., Lewis G., 2001. Links between social class and common mental disorders in 
Northeast Brazil. Social Psychiatry and Psychiatric Epidemiology, 36:101-107. 
 
Lund, C., Breen, A., Flisher, A. J., Kakuma R., Corrigall J., Joska, J. A., Swartz, L. & Patel, V., 
2010.  Poverty and common mental disorders in low and middle income countries: A systematic 
review, Social Science & Medicine, 71: 517-528. 
 
Magrini N., Vaccheri A., Parma E., D'Alessandro R., Bottoni A., Occhionero M., et al., 1996. 
Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk 
factors for use. Eur J Clin. Pharmacol., 50(1-2): 19-25. 
 
Melartin, T. K., Rytsälä, H. J., Leskelä, U. S., Lestelä-Mielonen, P. S., Sokero, P. T., Isometsä, 
E. T., 2005. Continuity is the main challenge in treating major depressive disorder in psychiatric 
care. Journal of Clinical Psychiatry, 66: 220–227. 
 
Mumford, D. B., Nazir, M., Jilani, F., Baig I.Y., 1996. Stress and psychiatric disorder in the 
Hindu Kush: a community survey of mountain villages in Chitral, Pakistan. British Journal of 
Psychiatry, 168:299-307. 
 
Neutel C. I., 2005. The epidemiology of long-term benzodiazepine use. International Review of 
Psychiatry,17(3): 189-97. 
 
44 
 
NICE (National Institute for Health and Clinical Excellence), 2004. Anxiety, Management of 
anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults 
in primary, secondary and community care. Clinical Guideline, vol. 22. Online access: 
www.nice.org.uk. 
Norwegian meteorological institute. www.met.no 
Norwegian prescription database. www.norpd.no 
Ohayon, M., 1996. Epidemiological study on insomnia in the general population. Sleep. 19 
(3Suppl):7-15 
 
Parikh, S. V., Lesage, A. D., Kennedy, S. H., Goering, P. N., 1999. Depression in Ontario: 
under-treatment and factors related to antidepressant use. Journal of Affective Disorders, 52: 67–
76. 
 
Patel, V., Kirkwood, B. R., Pednekar, S., Weiss, H., and Mabey, D., 2006. Risk factors for 
common mental disorders in women. Population-based longitudinal study. British Journal of 
Psychiatry, 189: 547-555. 
 
Patten, S. B., Esposito, E., Carter, B., 2007. Reasons for antidepressant prescriptions in Canada. 
Pharmacoepidemiology Drug Safety, 16: 746–752. 
 
Paulose-Ram, R., Jonas, B. S., Orwig, D., Safran, M. A., 2004. Prescription psychotropic 
medication use among the U.S. adult population: results from the third National Health and 
Nutrition Examination Survey, 1988-1994. J Clin. Epidemiol., 57(3): 309-17. 
 
Roberts, R. E., Shema, S. J., Kaplan, G. A., Strawbridge, W. J., 2000. Sleep complaints and 
depression in an aging cohort: a prospective perspective. American Journal of Psychiatry, 157: 
81–88. 
 
Rojas, G., Fritsch, R., Gaete, J., Gonzalez, I., Araya, R., 2005. Use of psychotropic medication in 
Santiago, Chile. Journal of Mental Health, 14(4): 407-414. 
 
Rønning, M., Sakshaug, S., Strøm, H., Berg, C. L., Litleskare, I., Blix, H. S. &Granum, T., 2010. 
Drug Consumption in Norway 2005-2009 (Legemiddelforbruket I Norge 2005-2009. 
Legemiddelstatistikk 2010:1), Norwegian Institute of Public Health. 
Sihvo, S., Isometsa, E., Kiviruusu, O., Hamalainen, J., Suvisaari, J., Perala, J., Pirkola, S., Saarni, 
S., Lonnqvis, J., 2008. Antidepressant utilization patterns and determinants of short term and 
non-psychiatric use in the Finnish general adult population. J Affective Disorders, 110: 94-105. 
Skurtveit, S., Rosvold, E.O., Furu, K., 2005. Use of psychotropic drugs in an urban adolescent 
population: the impact of health-related variables, lifestyle and socio demographic factors - The 
Oslo Health Study 2000-2001. Pharmaco epidemiology and Drug Safety, 14:277-283. 
45 
 
 
Sleath, B., Svarstad, B., Roter, D., 1998. Patient race and psychotropic prescribing during 
medical encounters. Patient Education and Counseling, 34:231-242. 
Statistics Norway. www.ssb.no 
Swartz, M., Landerman, R., George, L. K., Melville, M. L., Blazer, D., Smith, K., 1991. 
Benzodiazepine anti-anxiety agents: Prevalence and correlates of use in Southern community. 
American Journal of PublicHealth, 81: 592-596. 
 
Tomasson, K., Tomasson, H., Zoega, T., Sigfusson, E. & Helgason, T., 2007. Epidemiology of 
psychotropic medication use: comparison of sales, prescriptions and survey data in Iceland. Nord 
J Psychiatry, 61:471-478. 
 
Vlahovic´-Palcˇevski, V., Gantumur, M., Radosˇevic´, N., Palcˇevski, G. &Stichele, R. V., 2010. 
Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database. 
Pharm World Sci, 32:125–129. 
 
Voyer, P., Cohen, D., Lauzon, S., Collin, J., 2004. Factors associated with psychotropic drug use 
among community-dwelling older persons: A review of empirical studies. Bio Med Central. 
http://www.biomedcentral.com/1472-6955/3/3. 
 
Walsh, J.K., 2004. Pharmacologic management of insomnia. Journal of Clinical Psychiatry, 65 
(Suppl 16): 41–45. 
 
Weich, S., & Lewis, G., 1998. Poverty, unemployment, and common mental disorders: 
population based cohort study. British Medical Journal, 317: 115-119. 
 
Wells, K. B., Kamberg, C., Brook, R., Camp, P., Rogers, W., 1985. Health status, socio 
demographic factors, and the use of prescribed psychotropic drugs. Medical Care, 23: 11:1295-
1306. 
 
WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/. Last 
accessed 25 July 2013. 
 
 
